Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on September 14, 2016, regarding events occurring on September 8, 2016. The filing details the entry into a material definitive agreement for an underwritten secondary public offering of the company's Class A common stock.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a secondary stock offering.
Material Changes and Transaction Details
- Transaction Type: Underwritten secondary public offering of 7,500,000 shares of Class A common stock.
- Sellers: Shares were sold by "Selling Stockholders," including certain affiliates of TPG Global, LLC (TPG Funds), The Advisory Board Company, UPMC, Ptolemy Capital, LLC, and certain management selling stockholders.
- Company Proceeds: As this is a secondary offering, the proceeds are received by the Selling Stockholders, not Evolent Health, Inc.
- Underwriters: J.P. Morgan Securities LLC and Goldman, Sachs & Co. served as representatives.
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to 1,125,000 additional shares from the Investor Stockholders.
- Closing Date: The offering closed on September 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of new shares into the public market and the customary indemnification provisions within the Underwriting Agreement. The filing notes that certain affiliates of the TPG Funds are broker-dealers but confirmed they purchased the shares in the ordinary course of business without prior distribution agreements.
Investor Verification Checklist
- Verify the final number of shares sold, including whether the underwriters exercised the 1,125,000 share over-allotment option.
- Confirm the specific identity of the Selling Stockholders and the percentage of total outstanding shares they sold.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and lock-up provisions.
- Check subsequent filings (e.g., Form 4) to track the post-offering ownership stakes of major investors like TPG Funds and UPMC.